Literature DB >> 22513743

Renal interstitial hyaluronan: functional aspects during normal and pathological conditions.

Sara Stridh1, Fredrik Palm, Peter Hansell.   

Abstract

The glycosaminoglycan (GAG) hyaluronan (HA) is recognized as an important structural component of the extracellular matrix, but it also interacts with cells during embryonic development, wound healing, inflammation, and cancer; i.e., important features in normal and pathological conditions. The specific physicochemical properties of HA enable a unique hydration capacity, and in the last decade it was revealed that in the interstitium of the renal medulla, where the HA content is very high, it changes rapidly depending on the body hydration status while the HA content of the cortex remains unchanged at very low amounts. The kidney, which regulates fluid balance, uses HA dynamically for the regulation of whole body fluid homeostasis. Renomedullary HA elevation occurs in response to hydration and during dehydration the opposite occurs. The HA-induced alterations in the physicochemical characteristics of the interstitial space affects fluid flux; i.e., reabsorption. Antidiuretic hormone, nitric oxide, angiotensin II, and prostaglandins are classical hormones/compounds involved in renal fluid handling and are important regulators of HA turnover during variations in hydration status. One major producer of HA in the kidney is the renomedullary interstitial cell, which displays receptors and/or synthesis enzymes for the hormones mentioned above. During several kidney disease states, such as ischemia-reperfusion injury, tubulointerstitial inflammation, renal transplant rejection, diabetes, and kidney stone formation, HA is upregulated, which contributes to an abnormal phenotype. In these situations, cytokines and other growth factors are important stimulators. The immunosuppressant agent cyclosporine A is nephrotoxic and induces HA accumulation, which could be involved in graft rejection and edema formation. The use of hyaluronidase to reduce pathologically overexpressed levels of tissue HA is a potential therapeutic tool since diuretics are less efficient in removing water bound to HA in the interstitium. Although the majority of data describing the role of HA originate from animal and cell studies, the available data from humans demonstrate that an upregulation of HA also occurs in diabetic kidneys, in transplant-rejected kidneys, and during acute tubular necrosis. This review summarizes the current knowledge regarding interstitial HA in the role of regulating kidney function during normal and pathological conditions. It encompasses mechanistic insights into the background of the heterogeneous intrarenal distribution of HA; i.e., late nephrogenesis, its regulation during variations in hydration status, and its involvement during several pathological conditions. Changes in hyaluronan synthases, hyaluronidases, and binding receptor expression are discussed in parallel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513743     DOI: 10.1152/ajpregu.00332.2011

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  19 in total

Review 1.  Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis.

Authors:  Hans-Joachim Anders; Liliana Schaefer
Journal:  J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 10.121

2.  Network Pharmacology-Based Exploration of the Therapeutic Mechanisms of Cordyceps cicadae in Renal Ischemia/Reperfusion.

Authors:  Jiajun Dong; Mingyang Cao; Hui Yu; Yang Dong; Conghui Han
Journal:  Ann Transplant       Date:  2022-09-30       Impact factor: 1.479

3.  Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease.

Authors:  Antonella Mosca; Alessandro Mantovani; Annalisa Crudele; Nadia Panera; Donatella Comparcola; Rita De Vito; Marzia Bianchi; Christopher D Byrne; Giovanni Targher; Anna Alisi
Journal:  Front Pediatr       Date:  2022-06-06       Impact factor: 3.569

4.  Tissue-specific Fixation Methods Are Required for Optimal In Situ Visualization of Hyaluronan in the Ovary, Kidney, and Liver.

Authors:  Jennifer E Rowley; Gillian E Rubenstein; Sharrόn L Manuel; Natalie L Johnson; Jordan Surgnier; Pinelopi P Kapitsinou; Francesca E Duncan; Michele T Pritchard
Journal:  J Histochem Cytochem       Date:  2019-11-12       Impact factor: 2.479

Review 5.  Modulation of hyaluronan signaling as a therapeutic target in human disease.

Authors:  Stavros Garantziotis
Journal:  Pharmacol Ther       Date:  2021-09-26       Impact factor: 12.310

Review 6.  Tissue-specific parameters for the design of ECM-mimetic biomaterials.

Authors:  Olivia R Tonti; Hannah Larson; Sarah N Lipp; Callan M Luetkemeyer; Megan Makam; Diego Vargas; Sean M Wilcox; Sarah Calve
Journal:  Acta Biomater       Date:  2021-04-18       Impact factor: 10.633

7.  The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?

Authors:  Federica Genovese; Alba A Manresa; Diana Julie Leeming; Morten Asser Karsdal; Peter Boor
Journal:  Fibrogenesis Tissue Repair       Date:  2014-03-28

8.  Inhibition of mTOR activity in diabetes mellitus reduces proteinuria but not renal accumulation of hyaluronan.

Authors:  Sara Stridh; Fredrik Palm; Tomoko Takahashi; Mayumi Ikegami-Kawai; Peter Hansell
Journal:  Ups J Med Sci       Date:  2015-07-14       Impact factor: 2.384

9.  Inhibition of hyaluronan synthesis in rats reduces renal ability to excrete fluid and electrolytes during acute hydration.

Authors:  Sara Stridh; Fredrik Palm; Peter Hansell
Journal:  Ups J Med Sci       Date:  2013-09-09       Impact factor: 2.384

10.  A hyaluronan synthesis inhibitor delays the progression of diabetic kidney disease in a mouse experimental model.

Authors:  Guillermo Selman; Laisel Martinez; Andrea Lightle; Alejandra Aguilar; Daniel Woltmann; Yuxuan Xiao; Roberto I Vazquez-Padron; Loay H Salman
Journal:  Kidney360       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.